These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 24332674)

  • 61. Heart Rate Control With If Inhibitor, Ivabradine, in Japanese Patients With Chronic Heart Failure　- A Randomized, Double-Blind, Placebo-Controlled Phase II Study.
    Tsutsui H; Momomura S; Yamashina A; Ogawa H; Shimokawa H; Kihara Y; Saito Y; Hagiwara N; Ito H; Ako J; Inomata T; Tanaka T; Kawasaki Y;
    Circ J; 2016; 80(3):668-76. PubMed ID: 26763489
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Heart rate reduction with ivabradine in patients with acute decompensated systolic heart failure.
    Sargento L; Satendra M; Longo S; Lousada N; dos Reis RP
    Am J Cardiovasc Drugs; 2014 Jun; 14(3):229-35. PubMed ID: 24452599
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Ivabradine, a novel medication for treatment of heart failure with reduced ejection fraction.
    Foster JL; Bobadilla RV
    J Am Assoc Nurse Pract; 2016 Nov; 28(11):576-582. PubMed ID: 27215699
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT.
    Böhm M; Lloyd SM; Ford I; Borer JS; Ewen S; Laufs U; Mahfoud F; Lopez-Sendon J; Ponikowski P; Tavazzi L; Swedberg K; Komajda M
    Eur J Heart Fail; 2016 Jun; 18(6):672-83. PubMed ID: 26952245
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.
    Tardif JC; O'Meara E; Komajda M; Böhm M; Borer JS; Ford I; Tavazzi L; Swedberg K;
    Eur Heart J; 2011 Oct; 32(20):2507-15. PubMed ID: 21875858
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States.
    Borer JS; Kansal AR; Dorman ED; Krotneva S; Zheng Y; Patel HK; Tavazzi L; Komajda M; Ford I; Böhm M; Kielhorn A
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1064-71. PubMed ID: 27579829
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.
    Fox K; Ford I; Steg PG; Tendera M; Robertson M; Ferrari R;
    Eur Heart J; 2009 Oct; 30(19):2337-45. PubMed ID: 19720635
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Limited role for ivabradine in the treatment of chronic heart failure.
    Cullington D; Goode KM; Cleland JG; Clark AL
    Heart; 2011 Dec; 97(23):1961-6. PubMed ID: 21917660
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Role of ivabradine and heart rate lowering in chronic heart failure: guideline update.
    Chow SL; Page RL; Depre C
    Expert Rev Cardiovasc Ther; 2018 Jul; 16(7):515-526. PubMed ID: 29902387
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failure--the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study.
    Linde C; Gold M; Abraham WT; Daubert JC;
    Am Heart J; 2006 Feb; 151(2):288-94. PubMed ID: 16442890
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Digoxin and clinical outcomes in systolic heart failure patients on contemporary background heart failure therapy.
    Dhaliwal AS; Bredikis A; Habib G; Carabello BA; Ramasubbu K; Bozkurt B
    Am J Cardiol; 2008 Nov; 102(10):1356-60. PubMed ID: 18993155
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The effects of ivabradine on left atrial electromechanical function in patients with systolic heart failure.
    Ozturk S; Öztürk S; Erdem FH; Erdem A; Ayhan S; Dönmez İ; Yazıcı M
    J Interv Card Electrophysiol; 2016 Sep; 46(3):253-8. PubMed ID: 27039084
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effects of heart rate reduction with ivabradine on the international ındex of erectile function (IIEF-5) in patients with heart failure.
    Mert KU; Dural M; Mert GÖ; Iskenderov K; Özen A
    Aging Male; 2018 Jun; 21(2):93-98. PubMed ID: 28844168
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Ivabradine in stable coronary artery disease without clinical heart failure.
    Fox K; Ford I; Steg PG; Tardif JC; Tendera M; Ferrari R;
    N Engl J Med; 2014 Sep; 371(12):1091-9. PubMed ID: 25176136
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Ivabradine Improves Cardiac Function and Increases Exercise Capacity in Patients with Chronic Heart Failure.
    Pei H; Miao W; Xie WZ; Wang W; Zhao D; Su GH; Zhao Z
    Int Heart J; 2019 Jul; 60(4):899-909. PubMed ID: 31308326
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction.
    Udelson JE; Bilsker M; Hauptman PJ; Sequeira R; Thomas I; O'Brien T; Zimmer C; Orlandi C; Konstam MA
    J Card Fail; 2011 Dec; 17(12):973-81. PubMed ID: 22123358
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Is There a Role for Ivabradine in the Contemporary Management of Patients with Chronic Heart Failure in Academic and Community Heart Failure Clinics in Canada?
    Roth S; Fernando C; Azeem S; Moe GW
    Adv Ther; 2017 Jun; 34(6):1340-1348. PubMed ID: 28432646
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Ivabradine: Current and Future Treatment of Heart Failure.
    Thorup L; Simonsen U; Grimm D; Hedegaard ER
    Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):89-97. PubMed ID: 28371247
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Predictors of mortality from pump failure and sudden cardiac death in patients with systolic heart failure and left ventricular dyssynchrony: results of the CARE-HF trial.
    Uretsky BF; Thygesen K; Daubert JC; Erdmann E; Freemantle N; Gras D; Kappenberger L; Tavazzi L; Cleland JG
    J Card Fail; 2008 Oct; 14(8):670-5. PubMed ID: 18926439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.